© BioMed Central Ltd 2007
Published: 29 June 2007
Skip to main content
© BioMed Central Ltd 2007
Published: 29 June 2007
Inflammation and degradation of bone are two closely linked processes. Chronic inflammatory arthritis not only leads to inflammatory bone loss but it also involves local erosion of articular bone. This osteo-destructive feature of chronic inflammatory arthritis is a major cause of disability in patients with rheumatoid arthritis. Osteoclasts are essential for the resorption of mineralized cartilage and subchondral bone in chronic arthritis. The observed up-regulation of osteoclast differentiation factors (receptor activator of nuclear factor-κB ligand [RANKL]) in the synovial membrane of chronically inflamed joints indicates that osteoclasts are abundant in this setting, leading to rapid degradation of mineralized tissue. Blockade of osteoclast formation is thus a key strategy in preventing structural damage in arthritis. Denosumab, a humanized antibody that neutralizes RANKL, is an attractive candidate agent to inhibit inflammatory bone loss.
Pathologic changes in bone mass and bone quality can be the manifestation of an intrinsic, often genetically based dysfunction of the skeletal system, which can lead to fragile or otherwise altered bone. Osteogenesis imperfecta or Paget's disease are among the best known examples of primary genetically based bone disease; the former leads to fragile bone and the latter to increased bone mass. More frequently, however, bone becomes the target of extraskeletal processes, and changes in the exogenous or endogenous environment can affect skeletal tissue, accelerate bone loss, and decrease bone quality. Lack of mobility, smoking, and drug therapy are well established exogenous environmental factors that affect bone quality. Endogenous factors include age-induced loss of muscular strength and endocrine changes, such as reduction in sex hormones during the menopause or dysfunction of the thyroid or adrenal hormone axis.
Systemic inflammation is a key example of a condition that profoundly affects the skeleton but is not a primary disorder of bone itself. Recent data suggest that even a minor and subclinical increase in systemic inflammation precipitates bone disease and increases fracture risk . This tight interaction between inflammation and bone is highlighted by the observation that virtually all chronic inflammatory diseases, particularly rheumatic disease and chronic inflammatory bowel disease, are associated with a high prevalence of osteoporosis and increased fracture risk [2–6]. In the case of a more localized inflammatory process, these systemic effects on bone are accompanied by local bone damage at the skeletal sites closest to the inflammatory focus. Similar to destruction mediated by an earthquake, bone damage is most common and most severe in the vicinity of the (inflammatory) epicenter, whereas the effects are less severe at sites distant from the epicenter, although they can still be detected (for instance, bone density measurements in the case of bone loss). Local resorption of alveolar bone in periodontal disease is a good example of local bone loss; another clinically important example is bone erosion in inflammatory arthritis.
Signs of inflammatory bone erosion have been found in skeletal remains of individuals from several Indian tribes in Northern America . Destruction of bone by arthritis was first described more than 100 years ago. These earliest studies used histopathologic examination to investigate areas of structural joint damage . Later, with the development of radiographic imaging, bone erosions could be visualized directly and became not only part of the diagnostic criteria for RA but also a valuable tool for monitoring disease [9, 10]. Virtually all clinical studies of anti-inflammatory and immuno-modulatory drugs for the treatment of RA have employed clinical end-points as efficacy measures and radiologic endpoints to define drug effects on structural damage. Importantly, the resorption of mineralized tissue that is evident on conventional radiographs is strongly associated with poor functional outcome in patients with chronic arthritis [11–13]. With the ultimate aim being to preserve functional status and joint architecture in RA patients, characterization of early disease has been an important goal in RA research over the past 10 years. It soon became evident that bone erosion starts early in disease and progresses most rapidly during the first year . These findings have fostered the concepts that retardation, arrest, or even repair of structural damage should be considered central goals in the treatment of RA.
The early and rapid occurrence of structural damage in RA originates from a close interaction of the synovial membrane of the joint cavity and of the tendon sheaths with cartilage and subchondral bone. By definition, synovial tissue becomes inflamed during the course of arthritis and simultaneously involves adjacent cartilage and bone. In particular, synovial tissue close to the joint ends plays a central role in initiating structural damage . Studies of joints from animals and humans have shown that this layer of mineralized cartilage is rapidly resorbed, whereas the unmineralized surface cartilage remains intact for a certain period of time.
The observations that osteoclasts are an integral part of the mixed cellular infiltrate of inflammatory arthritis and that accumulation of these cells at sites of structural damage suggest that molecules involved in osteoclast formation are important players in the destructive processes of the disease. Receptor activator of nuclear factor-κB ligand (RANKL) exists in two different isoforms: a transmembrane cell-bound form and a soluble from, which shares structural similarities with tumor necrosis factor (TNF) but which binds to a different receptor, termed receptor antagonist of nuclear factor-κB (RANK) . Interaction of lower affinity with another member of the TNF receptor family, namely TNF-related apoptosis-inducing ligand, has also been described. The interaction between RANKL and RANK is crucial for osteoclast formation as well as lymph node organogenesis .
Mice that are unable to express either RANKL or RANK are osteopetrotic because of a complete lack of osteoclasts. These animals also exhibit complete developmental arrest of the lymph node anlagen during embryogenesis [20, 21]. Inhibition rather than absence of RANKL is achieved by over-expression of the natural inhibitor of RANK/RANK, namely osteoprotegerin (OPG). Whereas lymph node anlagen develop normally in mice that over-express OPG, the bone phenotype is very similar to that in RANKL and RANK knockout mice, because these animals have few osteoclasts and are osteopetrotic . Also, preclical studies of RANKL inhibition demonstrated normal immune responses .
RANKL is expressed in synovial tissue in chronic inflammatory arthritides such as RA and psoriatic arthritis [24–27]. Expression can be found on T and B cells and on synovial fibroblasts. Importantly, many proinflammatory cytokines, including TNF, IL-1, IL-6, and IL-17, are important inducers of RANKL expression, as is prostaglandin E2 . This plethora of inflammatory mediators in arthritis facilitates expression of RANKL, which engages its ligand RANK on monocytic cells, a population that is abundant in inflammatory synovial tissue. Formation of osteoclasts and their precursor cells is thus rapid, early, and triggered by continuous cytokine production and cell influx. In accordance with this, kinetic analyses of osteoclast formation in animal models of arthritis have revealed that cells form only a few days after the onset of inflammation .
The role played by RANKL in inflammatory bone destruction has been intensively characterized in experimental models of arthritis. In particular, mouse models with a genetic block in osteoclast formation have permitted new insights into the mechanisms of arthritis. For example, osteopetrotic mice such as c-fos-/- mice, RANKL-/- mice, and RANK-/- mice develop arthritis but do not exhibit bone erosion [30–32]. This switch from a destructive to a nondestructive phenotype not only proves that osteoclasts play a role in destruction of the joint architecture, but it also hints that blockade of RANKL might serve as an interesting approach to preventing inflammatory bone erosion.
It is not entirely clear whether RANKL blockade also affects proteoglycan loss in superficial articular cartilage. There is no doubt that targeting of osteoclasts would protect mineralized cartilage, an area that is highly sensitive to osteoclast-mediated resorption. Nonmineralized cartilage is not affected by osteoclasts, and it is therefore unlikely that RANKL blockade would affect this compartment directly. In some of the experimental arthritis models, however, protection against proteoglycan loss was observed following RANKL blockade, whereas it has not been observed in others. There are two potential explanations for the protection of surface cartilage after RANKL blockade. The first of these is a direct effect of RANKL blockade on cartilage by engagement of RANKL and RANK, which are expressed on articular chondrocytes . However, a specific function of RANK/RANKL on chondrocytes remains to be defined. A second possibility is an indirect protective effect on cartilage, based on prevention of resorption of mineralized cartilage attached to surface cartilage. Replacement of this interaction by an inflammatory tissue that attacks unmineralized cartilage not only from the surface (joint cavity) but also at the base may create a forceps-like destruction pattern that could dramatically affect the structure of this remaining surface cartilage. In this regard, inflammatory tissue not only creates aggrecanases and matrix metalloproteinases, which destroy the cartilage matrix, but it also leads to internal production of these enzymes by chondrocytes through the expression of proinflammatory cytokines. Thus, RANKL blockade probably affects the microenvironment of articular cartilage in inflammatory arthritis by preserving surrounding mineralized cartilage and bone.
Blockade of RANKL is considered a powerful future anti-resorptive strategy for the treatment of human bone disease. First proof of principal for this concept was derived from use of Fc:OPG as a blocker of RANKL; a single injection of this protein in humans resulted in increased bone mass and rapid decline in bone resorption parameters . This study was conducted in postmenopausal women with low bone mass. Recently, a fully human neutralizing antibody directed against RANKL, namely denosumab (formerly known as AMG 162), was developed that has sustained antiresorptive activity, lasting for up to 6 months after a single injection . Repeated injections of this antibody have resulted in profound and significant increases in bone mass at both axial and peripheral skeletal sites, as well as in trabecular and cortical areas of bone . Thus far, no major adverse effects of denosumab have been reported; this is reassuring, but further careful and long-term surveillance of infection rate and cardiovascular events are needed before conclusions regarding the long-term safety of this drug can be drawn. These findings make denosumab an attractive therapeutic tool for treating patients with RA. It is conceivable that the effects of denosumab extend not only to the prevention and treatment of generalized bone loss in RA but also to the prevention and treatment of joint destruction. A phase II study is currently underway that aims to investigate the role of RANKL blockade in inhibiting structural damage in RA, and preliminary data suggest that denosumab can indeed inhibit the process of bone erosion, as detected by magnetic resonance imaging of joints .
Although RANKL blockade does not inhibit inflammation, necessitating its combination with anti-inflammatory therapy, there are several rationales for targeting RANKL in human RA. First, structural damage often progresses despite use of disease-modifying antirheumatic drugs, especially in those patients who are not treated with TNF blockers. Second, structural damage is a leading cause of decreased joint function and disability in RA patients, emphasizing the need for effective drug therapy to preserve joint architecture. Finally, targeting of RANKL specifically and directly affects the mechanism responsible for the loss of mineralized cartilage and bone in chronic arthritis.
Chronic arthritis is an osteodestructive process, which leads to an accumulation of joint damage over time and prevents a restitutio ad integrum, as observed in spurious forms of arthritis. In addition to controlling inflammation, prevention of structural damage is a key objective of antirheumatic therapy. Because structural damage in RA is based on formation of osteoclasts in and around the joint, which resorb mineralized cartilage and subchondral bone, and because generation of these cells depends on RANKL, inhibition of this molecule is an interesting way to improve therapeutic outcomes in RA.
receptor activator of nuclear factor-κB
receptor activator of nuclear factor-κB ligand
tumor necrosis factor
This article is published as part of Arthritis Research & Therapy Volume 9 Supplement 1, 2007: Basic science, rationale, background and future of denosumab: a RANK ligand inhibitor. The full contents of the supplement are available online at http://arthritis-research.com/supplements/9/S1.
Publication of the supplement has been supported by an unrestricted grant from Amgen Inc.